Shares of Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.02 and traded as high as $2.00. Cortexyme shares last traded at $1.85, with a volume of 168,423 shares trading hands.
Cortexyme Stock Performance
The company has a 50-day moving average price of $1.61 and a 200-day moving average price of $1.03. The firm has a market capitalization of $53.67 million, a P/E ratio of -0.60 and a beta of 1.40.
About Cortexyme
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Featured Articles
- Five stocks we like better than Cortexyme
- ESG Stocks, What Investors Should Know
- Oil Titans Face Off: Exxon Mobil or Chevron for 2025 Gains?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Mining Stocks Back in the Spotlight: 3 Key Names to Watch
- Stock Market Upgrades: What Are They?
- MarketBeat Week in Review – 12/16 – 12/20
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
